In order to provide contract pharmaceutical packaging services for certain high-potency pharmaceutical products, Compass Pharma Services has announced the completion of a capital investment project to upgrade its production capabilities to include ISO Class 8 (ISO 14644) specifications.
The Clifton, New Jersey-based contract packaging company claims that capital improvements for ISO-Class 8 certification comprise a fully-integrated production suite, where the primary packaging area has negative differential air pressure relative to surrounding gowning and secondary packaging areas. High-Efficiency Particulate Air (HEPA) filters are deployed in the primary packaging area.
Tony Fenno, chief operating officer of Compass Pharma, said: “These capital improvements now allow us to provide cGMP contract packaging services for select potent pharmaceutical compounds such as enzymes, antibiotics, antifolates, antimetabolites and some hormones. Compass Pharma investments continue to position the company as a responsive contract pharmaceutical packaging partner for sophisticated, high-demand contract packaging services for the pharmaceutical industry.”
In February 2009, Compass Pharma added Micro and Nanofill packaging capabilities to its list of cGMP contract packaging capabilities. Reportedly, Micro and Nanofill technologies allow filling small volumes (less than one gram) of powders into blister packaging, vials or pouches.